Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review
Standard
Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review. / Dhayat, Sameer; Mardin, Wolf Arif; Mees, Soeren Torge; Haier, Joerg.
In: INT J CANCER, Vol. 129, No. 5, 01.09.2011, p. 1031-41.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Epigenetic markers for chemosensitivity and chemoresistance in pancreatic cancer--a review
AU - Dhayat, Sameer
AU - Mardin, Wolf Arif
AU - Mees, Soeren Torge
AU - Haier, Joerg
N1 - Copyright © 2011 UICC.
PY - 2011/9/1
Y1 - 2011/9/1
N2 - Adjuvant first-line gemcitabine monochemotherapy presents a standard treatment for patients with advanced pancreatic adenocarcinoma and improves overall survival in chemosensitive patients. Nonetheless, 6-month progression-free survival remains below 15%, despite interdisciplinary approaches. The success of gemcitabine treatment is disappointing and-in the absence of reliable tumor markers--challenging to quantify. Epigenetic alterations have been recently identified to take on important roles in cancer development and possibly cancer treatment. In this context, microRNAs are becoming increasingly acknowledged as useful biomarkers for classifying cancers and providing information on their chemo- and radiosensitivity. This review illustrates the potential of genetic and epigenetic markers in the prediction of chemosensitivity in pancreatic cancer patients and in the monitoring of their response rates to adjuvant therapy.
AB - Adjuvant first-line gemcitabine monochemotherapy presents a standard treatment for patients with advanced pancreatic adenocarcinoma and improves overall survival in chemosensitive patients. Nonetheless, 6-month progression-free survival remains below 15%, despite interdisciplinary approaches. The success of gemcitabine treatment is disappointing and-in the absence of reliable tumor markers--challenging to quantify. Epigenetic alterations have been recently identified to take on important roles in cancer development and possibly cancer treatment. In this context, microRNAs are becoming increasingly acknowledged as useful biomarkers for classifying cancers and providing information on their chemo- and radiosensitivity. This review illustrates the potential of genetic and epigenetic markers in the prediction of chemosensitivity in pancreatic cancer patients and in the monitoring of their response rates to adjuvant therapy.
KW - Antineoplastic Combined Chemotherapy Protocols
KW - Biomarkers, Tumor
KW - Drug Resistance, Neoplasm
KW - Humans
KW - Pancreatic Neoplasms
U2 - 10.1002/ijc.26078
DO - 10.1002/ijc.26078
M3 - SCORING: Journal article
C2 - 21413017
VL - 129
SP - 1031
EP - 1041
JO - INT J CANCER
JF - INT J CANCER
SN - 0020-7136
IS - 5
ER -